Patents by Inventor Paul D. Rubin

Paul D. Rubin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions using (?) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
    Patent number: 6362202
    Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: March 26, 2002
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
    Patent number: 6353005
    Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: March 5, 2002
    Assignee: Sepracor, Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Methods of making and using N-desmethylzopiclone
    Publication number: 20020019398
    Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.
    Type: Application
    Filed: June 11, 2001
    Publication date: February 14, 2002
    Applicant: SEPRACOR, Inc.
    Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville
  • Methods of making and using N-desmethylzopiclone
    Patent number: 6339086
    Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: January 15, 2002
    Assignee: Swpracor, Inc.
    Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Fran A. McConville
  • S-rabeprazole compositions and methods
    Publication number: 20010034354
    Abstract: Methods and compositions are disclosed utilizing optically pure (−) rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: May 25, 2001
    Publication date: October 25, 2001
    Inventors: Patrick Koch, Paul D. Rubin, William E. Yelle
  • S-lansoprazole compositions and methods
    Publication number: 20010025107
    Abstract: Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: May 11, 2001
    Publication date: September 27, 2001
    Inventors: Timothy J. Barberich, William E. Yelle, Paul D. Rubin
  • Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion
    Publication number: 20010011103
    Abstract: Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.
    Type: Application
    Filed: March 13, 2001
    Publication date: August 2, 2001
    Applicant: Sepracor Inc.
    Inventors: John R. McCullough, Paul D. Rubin
  • Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
    Patent number: 6248308
    Abstract: Methods and pharmaceutical compositions employing norastemizole and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof. Also included are methods and compositions employing norastemizole and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: June 19, 2001
    Assignee: Sepracor Inc.
    Inventor: Paul D. Rubin
  • Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
    Patent number: 6194431
    Abstract: Methods and pharmaceutical compositions employing a terfenadine metabolite and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof. Also included are methods and compositions employing a terfenadine metabolite, a leukotriene inhibitor, and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: February 27, 2001
    Inventor: Paul D. Rubin
  • R-rabeprazole compositions and methods
    Patent number: 6174902
    Abstract: Methods and compositions are disclosed utilizing optically pure (+) rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure (+) isomer is also useful for the treatment of gastroesophageal reflux. (+) Rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: January 16, 2001
    Assignee: Sepracor Inc.
    Inventors: William E. Yelle, Paul D. Rubin, Patrick Koch
  • Methods for treating dermatitis using descarboethoxyloratadine
    Patent number: 6054463
    Abstract: The invention relates to methods of utilizing descarboethoxyloratadine ("DCL") for the treatment of dermatitis. The invention also encompasses the topical administration of descarboethoxyloratadine using various dosage forms for the treatment of dermatitis.
    Type: Grant
    Filed: March 17, 1999
    Date of Patent: April 25, 2000
    Assignee: Sepracor Inc.
    Inventors: Dean A. Handley, Paul D. Rubin
  • Methods for treating apnea, apnea disorders, bulimia, and other disorders using optically pure (+) norcisapride
    Patent number: 6048879
    Abstract: Methods for the prevention, treatment or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: April 11, 2000
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Methods and compositions for treating allergic asthma using descarboethoxyloratadine
    Patent number: 5962464
    Abstract: Methods utilizing descarboethoxyloratadine ("DCL"), for the treatment of allergic disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. Also included are methods for the treatment of allergic asthma using DCL and either a decongestant or a leukotriene inhibitor, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. The invention also encompasses the administration of DCL in a nasal or oral spray.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: October 5, 1999
    Assignee: Sepracor Inc.
    Inventors: Dean A. Handley, Paul D. Rubin
  • Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
    Patent number: 5900421
    Abstract: Methods utilizing descarboethoxyloratadine ("DCL"), for the treatment of allergic disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. Also included are methods for the treatment of allergic asthma using DCL and either a decongestant or a leukotriene inhibitor, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. The invention also encompasses the administration of DCL in a nasal or oral spray.
    Type: Grant
    Filed: February 11, 1997
    Date of Patent: May 4, 1999
    Assignee: Sepracor Inc.
    Inventors: Dean A. Handley, Paul D. Rubin